The chairman of the National Immunization Advisory Council described the announcement of a 94.5 percent protection rate against Modina’s Kovid – 19 vaccine as “very exciting news.”

Professor Kareena Butler, an infectious disease specialist at the Royal College of Physicians, said the vaccine was not needed. Same ultra-cold storage as Pfizer It was “an important achievement.”

News of Second successful Kovid-19 vaccine trial “It was an extraordinary day,” she told RTE Radio’s News at One.

The modern vaccine is expected to stabilize at standard refrigerator temperatures of 2 to 8 ൽ C for 30 days and can be stored at -20 C for up to six months.

Fischer vaccine should be stored at -70 degrees Celsius, the normal winter temperature in Antarctica. At normal refrigerator temperature, it can be stored for up to five days.

A lot of work has already been done Based on the plan for vaccine distribution, Prof. Butler said.

Priority is given to those who are in need, as well as those who are likely to be adversely affected, as well as health care workers.

Side effects

When asked if the vaccine was fast, Prof. Butler said: “Is it too fast?” When the two studies are combined there are very large numbers, most are not all, but most side effects can be detected within six weeks. ”

Most of the side effects identified in the modern study were mild and moderate. However, a large section of the volunteers experienced more severe aches and pains after taking the second dose.

The company said most of these complaints were generally short-lived.

Modena is the second company to report results from the corona virus vaccine in less than a week Pfizer and Biotech said the vaccine offered 90 percent protection against Kovid-19.

That means this technology is reproducible, and if you will, it gives us more hope

Speaking this morning before Modena’s announcement, Luke O’Neill, a professor of immunology at Trinity College Dublin, said both results were a sign of hope.

“If they get the same level of effectiveness, it’s a great result, because it means two completely different companies get the same result, which is independent of each other,” he said.

“That means this technology can be redesigned, and if you want, it gives us more hope.”

Vaccines made using a new technology known as messenger RNA or MRNA represent a powerful new tool to combat an epidemic that has affected 54 million people worldwide and killed 1.3 million.